Myocardial Infarction: Promising Therapies Advance Through Clinical Trials
Key Insights
Several companies are actively developing innovative therapies for myocardial infarction (search), with Idorsia Pharmaceuticals (search) leading the way with its Phase III drug, selatogrel.
Faraday Pharmaceuticals (search)' FDY-5301, an elemental reducing agent, is under Phase 3 evaluation with an SPA agreement from the FDA for treating acute ST-segment elevation myocardial infarction (search) (STEMI (search)).
Novel approaches such as stem cell therapies and anti-inflammatory agents like Dapansutrile are being explored to improve outcomes and reduce cardiac injury post-myocardial infarction (search).
Myocardial infarction (search) (MI), commonly known as a heart attack, occurs when blood flow to the heart is blocked, often by a buildup of plaque in the arteries, leading to oxygen deprivation and potential damage to the heart muscle. Several companies are currently developing therapies to combat this critical condition. According to DelveInsight’s “Myocardial Infarction Pipeline Insight” report, over 40 companies are exploring more than 40 drugs in various stages of clinical development.
Late-Stage Clinical Developments
Idorsia Pharmaceuticals (search) is currently in Phase III clinical trials with selatogrel, a P2Y12 receptor (search) antagonist. The “SOS-AMI (search)” study is evaluating the efficacy and safety of self-administered subcutaneous selatogrel in patients with suspected acute myocardial infarction (search) (AMI). Selatogrel is designed for rapid action and reversibility, potentially offering a significant advantage in emergency situations.
CSL Behring is also in Phase III trials with CSL112, an apolipoprotein A-I infusion therapy. CSL112 aims to reduce the risk of major adverse cardiovascular events (MACE) in patients with Acute Coronary Syndrome (search) (ACS).
Novel Therapeutic Approaches
Faraday Pharmaceuticals (search) has reached an agreement with the FDA under a Special Protocol Assessment (SPA) for its Phase 3 cardiovascular outcomes study of FDY-5301. FDY-5301 is being evaluated for the treatment of acute ST-segment elevation myocardial infarction (search) (STEMI (search)) in patients undergoing percutaneous intervention (PCI). Preclinical studies have indicated that FDY-5301 can reduce cardiac and skeletal muscle injury, and Phase 2 data suggested a reduction in infarct size and improved cardiac function.
Ever Supreme Bio Technology Co. (search), Ltd. is exploring the use of umbilical cord mesenchymal stem cells (UMC01) for treating acute myocardial infarction (search) (AMI (search)). The therapy has received FDA and TFDA approval for Phase I clinical trials.
Olatec Therapeutics (search) is developing Dapansutrile, an anti-inflammatory agent with promising activity in preclinical models of acute myocardial infarction (search) (AMI (search)), among other conditions. Dapansutrile has demonstrated anti-inflammatory properties in over 20 preclinical animal models.
Athera Biotechnologies (search) is developing ATH3G10 (search), a first-in-class fully human antibody targeting phosphorylcholine (search) (PC), an epitope on damaged or stressed cells. This candidate is initially being developed for patients with large ST-elevation myocardial infarction (search) (STEMI (search)) who are at high risk of heart failure.
Addressing Unmet Needs
Despite existing treatments, there remains a significant unmet need for therapies that can further reduce cardiac injury and improve long-term outcomes following myocardial infarction (search). The diverse approaches in development, from receptor antagonists to stem cell therapies and anti-inflammatory agents, reflect a comprehensive effort to address these needs and improve patient care.